{
    "hands_on_practices": [
        {
            "introduction": "Mastering immunosuppressive therapy begins with the fundamental skill of calculating an initial, patient-specific dose. This practice grounds you in the first-principles of pharmacokinetics, requiring you to derive a maintenance dose for tacrolimus from target steady-state concentrations and key parameters like clearance and bioavailability. By working through this calculation , you will not only determine a starting dose but also critically evaluate the assumptions and limitations of the model, a crucial step in translating theory to safe clinical practice.",
            "id": "5133859",
            "problem": "A transplant service is initiating tacrolimus, a calcineurin inhibitor (CNI), for a stable adult kidney transplant recipient. Assume one-compartment, linear pharmacokinetics with first-order elimination, constant oral bioavailability, and time-invariant clearance. The following patient- and regimen-specific quantities are known or selected: adult mass $70$ kg (provided for clinical context), oral bioavailability $F = 0.25$, target steady-state average concentration $C_{\\mathrm{ss,avg}} = 8$ ng/mL, apparent clearance $CL = 35$ L/h, and proposed dosing interval $\\tau = 12$ h. Starting from fundamental mass balance at steady state and the definition that, for a linear system at steady state, the average elimination rate equals clearance times the average concentration, derive a maintenance-dose expression that yields the dose per interval required to achieve a specified steady-state average concentration under oral dosing. Then compute the initial tacrolimus dose per administration using the provided quantities. Round your numerical answer to four significant figures and express the dose in milligrams per dose. Finally, clearly state the key modeling assumptions under which your derivation holds and identify at least three clinically relevant limitations in the transplantation setting that could cause the true dose requirement to deviate from the calculated value.",
            "solution": "The problem is evaluated for validity.\n\n### Step 1: Extract Givens\n-   **Patient/Clinical Context**: Adult kidney transplant recipient, mass $70$ kg.\n-   **Drug**: Tacrolimus, a calcineurin inhibitor (CNI).\n-   **Pharmacokinetic Model**: One-compartment, linear pharmacokinetics, first-order elimination, constant oral bioavailability, time-invariant clearance.\n-   **Oral Bioavailability**: $F = 0.25$.\n-   **Target Steady-State Average Concentration**: $C_{\\mathrm{ss,avg}} = 8$ ng/mL.\n-   **Apparent Clearance**: $CL = 35$ L/h.\n-   **Dosing Interval**: $\\tau = 12$ h.\n-   **Task 1**: Derive a maintenance-dose expression.\n-   **Task 2**: Compute the initial tacrolimus dose per administration in milligrams.\n-   **Task 3**: Round the numerical answer to four significant figures.\n-   **Task 4**: State the key modeling assumptions.\n-   **Task 5**: Identify at least three clinically relevant limitations.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is well-defined and scientifically grounded in the principles of clinical pharmacokinetics, a core discipline in pharmacology and medicine.\n-   **Scientifically Grounded (Critical)**: The problem uses a standard one-compartment model with first-order elimination, which is a fundamental and widely applied simplification for determining dosing regimens for many drugs, including tacrolimus in its initial phase. The given parameter values ($F$, $CL$, $C_{\\mathrm{ss,avg}}$) are within the plausible range for an adult patient.\n-   **Well-Posed**: The problem provides all necessary parameters and a clear objective, leading to a unique analytical and numerical solution.\n-   **Objective (Critical)**: The problem is stated in precise, quantitative, and unbiased technical language.\n-   **Completeness and Consistency**: The provided data are sufficient and consistent. For instance, clearance is given in L/h and the dosing interval in hours, which are compatible units. The mass is correctly identified as contextual information. The conversion between concentration units (ng/mL) and dose units (mg) is a standard part of such calculations.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution Derivation and Calculation\n\n**Part 1: Derivation of the Maintenance Dose Expression**\n\nThe derivation begins with the principle of mass balance at steady state. At steady state ($ss$), the average rate of drug administration into the systemic circulation must equal the average rate of drug elimination from the body.\n\nThe average rate of drug administration is the total amount of drug that reaches the systemic circulation per dosing interval, $\\tau$. For an oral dose, denoted as $Dose$, with a constant oral bioavailability $F$, the amount of drug reaching the circulation is $F \\times Dose$. The average rate is this amount divided by the dosing interval $\\tau$:\n$$\n\\text{Rate}_{\\mathrm{in,avg}} = \\frac{F \\times Dose}{\\tau}\n$$\nThe problem states that for a linear system, the average rate of elimination at steady state is the product of the drug's apparent clearance, $CL$, and the average steady-state plasma concentration, $C_{\\mathrm{ss,avg}}$:\n$$\n\\text{Rate}_{\\mathrm{out,avg}} = CL \\times C_{\\mathrm{ss,avg}}\n$$\nEquating the rate in and the rate out at steady state:\n$$\n\\frac{F \\times Dose}{\\tau} = CL \\times C_{\\mathrm{ss,avg}}\n$$\nTo find the required maintenance dose per interval, we solve this equation for $Dose$:\n$$\nDose = \\frac{CL \\times C_{\\mathrm{ss,avg}} \\times \\tau}{F}\n$$\nThis is the general expression for the maintenance dose required to achieve a target average steady-state concentration.\n\n**Part 2: Computation of the Initial Dose**\n\nWe are given the following values:\n-   $CL = 35$ L/h\n-   $C_{\\mathrm{ss,avg}} = 8$ ng/mL\n-   $\\tau = 12$ h\n-   $F = 0.25$\n\nTo ensure dimensional consistency, we must convert the units of concentration to be compatible with the units of clearance. The dose is required in milligrams (mg). Clearance is in liters (L). Therefore, we convert $C_{\\mathrm{ss,avg}}$ from nanograms per milliliter (ng/mL) to milligrams per liter (mg/L).\n$$\n1 \\text{ ng} = 10^{-6} \\text{ mg}\n$$\n$$\n1 \\text{ mL} = 10^{-3} \\text{ L}\n$$\nTherefore, the conversion factor is:\n$$\n1 \\frac{\\text{ng}}{\\text{mL}} = \\frac{10^{-6} \\text{ mg}}{10^{-3} \\text{ L}} = 10^{-3} \\frac{\\text{mg}}{\\text{L}}\n$$\nApplying this to the target concentration:\n$$\nC_{\\mathrm{ss,avg}} = 8 \\frac{\\text{ng}}{\\text{mL}} = 8 \\times 10^{-3} \\frac{\\text{mg}}{\\text{L}}\n$$\nNow we can substitute the numerical values into the derived dose expression:\n$$\nDose = \\frac{(35 \\frac{\\text{L}}{\\text{h}}) \\times (8 \\times 10^{-3} \\frac{\\text{mg}}{\\text{L}}) \\times (12 \\text{ h})}{0.25}\n$$\nFirst, calculate the numerator:\n$$\n\\text{Numerator} = 35 \\times 8 \\times 10^{-3} \\times 12 \\text{ mg} = 3.36 \\text{ mg}\n$$\nThen, divide by the bioavailability, $F$:\n$$\nDose = \\frac{3.36 \\text{ mg}}{0.25} = 13.44 \\text{ mg}\n$$\nThe calculated dose is $13.44$ mg per administration. The problem requires rounding to four significant figures, which $13.44$ already has.\n\n**Part 3: Key Modeling Assumptions**\n\nThe derivation and calculation are valid under the following key modeling assumptions, which were explicitly provided or are implicit in the model structure:\n1.  **One-Compartment Model**: The drug is assumed to distribute instantaneously and uniformly throughout a single, kinetically homogeneous volume in the body.\n2.  **Linear Pharmacokinetics**: The rates of absorption, distribution, and elimination are all first-order processes. This implies that clearance ($CL$) and volume of distribution ($V_d$) are constants, independent of the drug concentration or dose administered.\n3.  **Time-Invariant Parameters**: The patient's pharmacokinetic parameters, specifically clearance ($CL$) and bioavailability ($F$), are assumed to be constant over time.\n4.  **Steady-State Condition**: The calculation assumes that the system has reached steady state, where the drug accumulation and elimination have balanced over a dosing interval. This typically occurs after $4$ to $5$ elimination half-lives.\n\n**Part 4: Clinically Relevant Limitations**\n\nThe calculated dose of $13.44$ mg is a theoretical starting point. In clinical practice, the true required dose can deviate significantly due to several factors not captured by this simplified model. At least three critical limitations include:\n\n1.  **Inter- and Intra-Patient Pharmacokinetic Variability**: The values for clearance ($CL$) and bioavailability ($F$) are population averages. An individual patient's actual parameters can vary substantially due to genetic factors (e.g., polymorphisms in the CYP3A5 enzyme, a major route of tacrolimus metabolism), hepatic function, and age. Intra-patient variability also occurs, where a patient's clearance can change over time due to recovery, illness, or other physiological shifts.\n2.  **Drug-Drug and Drug-Food Interactions**: Tacrolimus is a substrate of the cytochrome P450 3A (CYP3A) subfamily of enzymes and the P-glycoprotein efflux transporter. Concomitant administration of drugs that inhibit these pathways (e.g., azole antifungals, macrolide antibiotics, protease inhibitors) can dramatically decrease tacrolimus clearance, leading to toxicity. Conversely, inducers (e.g., rifampin, certain anticonvulsants) can increase clearance, leading to subtherapeutic levels and risk of rejection. Food, particularly high-fat meals, can also affect the rate and extent of tacrolimus absorption, altering its bioavailability.\n3.  **Gastrointestinal Pathophysiology**: The oral bioavailability ($F$) of tacrolimus is highly dependent on the integrity and function of the gastrointestinal tract. Conditions common in transplant patients, such as diarrhea, gastroparesis, or post-operative ileus, can severely and unpredictably alter drug absorption, making the assumed constant bioavailability of $F = 0.25$ unreliable and leading to significant deviations from the target concentration.",
            "answer": "$$\n\\boxed{13.44}\n$$"
        },
        {
            "introduction": "A frequent challenge in transplant medicine is the need to convert a patient from one immunosuppressive agent to another. This exercise  builds upon basic dosing principles by tasking you with a conversion from cyclosporine to tacrolimus, two drugs with distinct pharmacokinetic profiles. You will use a patient's stable response to the first drug to inform the dosing of the second, reinforcing how relative differences in bioavailability ($F$) and clearance ($CL$) directly guide dose adjustments.",
            "id": "5133902",
            "problem": "A kidney transplant recipient is being converted from cyclosporine to tacrolimus. The patient is currently taking cyclosporine $150$ mg every $12$ h with a stable trough concentration of $150$ ng/mL measured in whole blood. The dosing interval will remain $12$ h after the conversion. For cyclosporine in this patient, the whole-blood oral bioavailability is $F_{\\text{cyc}} = 0.30$ and the whole-blood clearance is $\\text{CL}_{\\text{cyc}} = 20$ L/h. For tacrolimus in this patient, the whole-blood oral bioavailability is $F_{\\text{tac}} = 0.25$ and the whole-blood clearance is $\\text{CL}_{\\text{tac}} = 5.0$ L/h. Assume linear one-compartment pharmacokinetics and steady state for both drugs, and use the following foundational relations: at steady state, the rate of drug input equals the rate of drug elimination, with $$\\text{Rate}_{\\text{in}} = \\frac{F \\cdot \\text{Dose}}{\\tau} \\quad \\text{and} \\quad C_{\\text{ss,avg}} = \\frac{\\text{Rate}_{\\text{in}}}{\\text{CL}},$$ where $F$ is oral bioavailability, $\\tau$ is the dosing interval, $\\text{CL}$ is clearance, and $C_{\\text{ss,avg}}$ is the steady-state average concentration. In clinical practice under twice-daily dosing for these agents, the trough concentration is proportional to the steady-state average concentration for a given patient and regimen; let this proportionality be $C_{\\text{trough}} = \\alpha \\, C_{\\text{ss,avg}}$.\n\nUsing the cyclosporine data provided, determine the patient-specific proportionality factor $\\alpha$. Then, using the target tacrolimus trough range of $6$ to $10$ ng/mL, compute the total daily tacrolimus dose that would be expected to achieve the midpoint of this range. Express the final dose in mg/day and round your answer to three significant figures. All necessary unit conversions must be performed explicitly (for example, $1$ ng/mL $=$ $10^{-3}$ mg/L).",
            "solution": "The problem statement is first subjected to validation.\n\n### Step 1: Extract Givens\n\n- **Cyclosporine (cyc) Data**:\n  - Dose: $150$ mg\n  - Dosing interval ($\\tau$): $12$ h\n  - Stable trough concentration ($C_{\\text{trough,cyc}}$): $150$ ng/mL\n  - Oral bioavailability ($F_{\\text{cyc}}$): $0.30$\n  - Whole-blood clearance ($\\text{CL}_{\\text{cyc}}$): $20$ L/h\n- **Tacrolimus (tac) Data**:\n  - Dosing interval ($\\tau$): $12$ h\n  - Oral bioavailability ($F_{\\text{tac}}$): $0.25$\n  - Whole-blood clearance ($\\text{CL}_{\\text{tac}}$): $5.0$ L/h\n  - Target trough range: $6$ to $10$ ng/mL\n- **Pharmacokinetic Relations and Assumptions**:\n  - Linear one-compartment pharmacokinetics.\n  - Steady-state conditions for both drugs.\n  - Rate of input equals rate of drug elimination: $\\text{Rate}_{\\text{in}} = \\frac{F \\cdot \\text{Dose}}{\\tau}$\n  - Steady-state average concentration: $C_{\\text{ss,avg}} = \\frac{\\text{Rate}_{\\text{in}}}{\\text{CL}}$\n  - Proportionality between trough and average concentration: $C_{\\text{trough}} = \\alpha \\, C_{\\text{ss,avg}}$\n- **Required Unit Conversion**: $1$ ng/mL $=$ $10^{-3}$ mg/L\n- **Objective**:\n  1. Determine the patient-specific proportionality factor $\\alpha$.\n  2. Compute the total daily tacrolimus dose (mg/day) to achieve the midpoint of the target trough range.\n  3. Round the final answer to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientifically Grounded**: The problem is based on standard, well-established pharmacokinetic principles used in therapeutic drug monitoring and dose conversion, specifically for immunosuppressants in transplant medicine. The provided parameters ($F$, $\\text{CL}$, concentrations) are within realistic clinical ranges.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data and equations to uniquely determine the requested quantities. The objective is clearly stated.\n- **Objective**: The problem is formulated using precise, quantitative language, free of subjectivity or ambiguity.\n\n### Step 3: Verdict and Action\n\nThe problem is scientifically sound, self-contained, and well-posed. It is deemed **valid**. The solution process will now proceed.\n\nThe solution is a two-part process. First, the patient-specific proportionality factor, $\\alpha$, is determined using the provided cyclosporine data. Second, this factor is used to calculate the required tacrolimus dose to achieve the target concentration.\n\n**Part 1: Determination of the Proportionality Factor $\\alpha$**\n\nThe steady-state average concentration, $C_{\\text{ss,avg}}$, is given by the ratio of the rate of drug input to the drug's clearance. The rate of input for an oral drug at steady state is the bioavailable fraction of the dose averaged over the dosing interval. Combining the given relations:\n$$C_{\\text{ss,avg}} = \\frac{\\text{Rate}_{\\text{in}}}{\\text{CL}} = \\frac{\\frac{F \\cdot \\text{Dose}}{\\tau}}{\\text{CL}} = \\frac{F \\cdot \\text{Dose}}{\\tau \\cdot \\text{CL}}$$\nFor cyclosporine, we can calculate $C_{\\text{ss,avg,cyc}}$ using the patient's data:\n- $\\text{Dose}_{\\text{cyc}} = 150 \\text{ mg}$\n- $\\tau_{\\text{cyc}} = 12 \\text{ h}$\n- $F_{\\text{cyc}} = 0.30$\n- $\\text{CL}_{\\text{cyc}} = 20 \\text{ L/h}$\n\nSubstituting these values:\n$$C_{\\text{ss,avg,cyc}} = \\frac{0.30 \\cdot 150 \\text{ mg}}{(12 \\text{ h}) \\cdot (20 \\text{ L/h})} = \\frac{45 \\text{ mg}}{240 \\text{ L}} = 0.1875 \\text{ mg/L}$$\nThe problem states a stable trough concentration for cyclosporine, $C_{\\text{trough,cyc}} = 150 \\text{ ng/mL}$. To maintain consistent units with $C_{\\text{ss,avg,cyc}}$, this value must be converted explicitly from ng/mL to mg/L:\n$$C_{\\text{trough,cyc}} = 150 \\frac{\\text{ng}}{\\text{mL}} = 150 \\frac{10^{-6} \\text{ mg}}{10^{-3} \\text{ L}} = 150 \\times 10^{-3} \\frac{\\text{mg}}{\\text{L}} = 0.150 \\text{ mg/L}$$\nThe proportionality factor $\\alpha$ is defined by the relation $C_{\\text{trough}} = \\alpha \\, C_{\\text{ss,avg}}$. We can now solve for $\\alpha$:\n$$\\alpha = \\frac{C_{\\text{trough,cyc}}}{C_{\\text{ss,avg,cyc}}} = \\frac{0.150 \\text{ mg/L}}{0.1875 \\text{ mg/L}} = 0.8$$\nThe factor $\\alpha$ is a dimensionless quantity.\n\n**Part 2: Calculation of the Total Daily Tacrolimus Dose**\n\nThe target trough range for tacrolimus is $6$ to $10 \\text{ ng/mL}$. The objective is to achieve the midpoint of this range:\n$$C_{\\text{trough,tac,target}} = \\frac{6 \\text{ ng/mL} + 10 \\text{ ng/mL}}{2} = 8 \\text{ ng/mL}$$\nAgain, we convert this target concentration to mg/L explicitly:\n$$C_{\\text{trough,tac,target}} = 8 \\frac{\\text{ng}}{\\text{mL}} = 8 \\frac{10^{-6} \\text{ mg}}{10^{-3} \\text{ L}} = 8 \\times 10^{-3} \\text{ mg/L}$$\nWe assume that the proportionality factor $\\alpha=0.8$ is a patient-specific characteristic that remains constant for the tacrolimus regimen, as both drugs are administered on the same twice-daily schedule. Using this $\\alpha$, we find the required average steady-state concentration for tacrolimus, $C_{\\text{ss,avg,tac,target}}$:\n$$C_{\\text{ss,avg,tac,target}} = \\frac{C_{\\text{trough,tac,target}}}{\\alpha} = \\frac{8 \\times 10^{-3} \\text{ mg/L}}{0.8} = 10 \\times 10^{-3} \\text{ mg/L} = 0.01 \\text{ mg/L}$$\nNow, we can calculate the required tacrolimus dose per dosing interval, $\\text{Dose}_{\\text{tac}}$, by rearranging the formula for $C_{\\text{ss,avg}}$:\n$$\\text{Dose}_{\\text{tac}} = \\frac{C_{\\text{ss,avg,tac,target}} \\cdot \\tau_{\\text{tac}} \\cdot \\text{CL}_{\\text{tac}}}{F_{\\text{tac}}}$$\nUsing the tacrolimus-specific parameters:\n- $\\tau_{\\text{tac}} = 12 \\text{ h}$\n- $\\text{CL}_{\\text{tac}} = 5.0 \\text{ L/h}$\n- $F_{\\text{tac}} = 0.25$\n\nSubstituting the values:\n$$\\text{Dose}_{\\text{tac}} = \\frac{(0.01 \\text{ mg/L}) \\cdot (12 \\text{ h}) \\cdot (5.0 \\text{ L/h})}{0.25} = \\frac{0.6 \\text{ mg}}{0.25} = 2.4 \\text{ mg}$$\nThis is the dose administered every $12$ hours. The problem asks for the total daily dose. Since the dosing interval is $12$ hours, there are two doses per day.\n$$\\text{Total Daily Dose}_{\\text{tac}} = \\text{Dose}_{\\text{tac}} \\times \\frac{24 \\text{ h/day}}{12 \\text{ h/dose}} = 2.4 \\text{ mg} \\times 2 = 4.8 \\text{ mg/day}$$\nThe problem requires the final answer to be rounded to three significant figures.\n$$\\text{Total Daily Dose}_{\\text{tac}} = 4.80 \\text{ mg/day}$$",
            "answer": "$$\\boxed{4.80}$$"
        },
        {
            "introduction": "Effective therapeutic drug monitoring goes beyond simply reading a lab value; it requires sophisticated interpretation in the context of a patient's changing physiology. This problem  explores the critical relationship between hematocrit and measured whole blood tacrolimus concentrations, a consequence of the drug's extensive binding to red blood cells. By modeling this relationship, you will learn why a drop in the measured trough level during anemia may not signify true underexposure, preventing potential over-immunosuppression from a misinformed dose increase.",
            "id": "5133757",
            "problem": "A kidney transplant recipient is treated with tacrolimus and monitored using whole blood trough concentrations. The patient is clinically stable with unchanged dosing and adherence. At baseline, the red blood cell (RBC) volume fraction, that is, the hematocrit (Hct), is $H_1 = 0.40$, and the measured whole blood tacrolimus trough concentration is $C_{\\mathrm{WB,1}} = 8\\ \\mathrm{ng/mL}$. Three weeks after a gastrointestinal bleed, the patient’s Hct decreases to $H_2 = 0.25$, and the measured whole blood trough concentration is $C_{\\mathrm{WB,2}} = 6\\ \\mathrm{ng/mL}$, with dosing and clinical status otherwise unchanged. Assume tacrolimus rapidly equilibrates between RBCs and plasma, binds strongly within RBCs, and exhibits an approximately constant RBC-to-plasma partition coefficient $K$ over the therapeutic range, defined by $K = \\dfrac{C_{\\mathrm{RBC}}}{C_{\\mathrm{plasma}}}$ at equilibrium. \n\nUsing the following fundamental bases:\n- Conservation of mass and mixture concentration: for any two-compartment mixture (here RBCs and plasma) in which the total is the volume-fraction-weighted average of compartment concentrations, the whole blood concentration satisfies\n$$\nC_{\\mathrm{WB}} = H\\,C_{\\mathrm{RBC}} + (1-H)\\,C_{\\mathrm{plasma}}.\n$$\n- The definition of the partition coefficient $K$:\n$$\nK = \\dfrac{C_{\\mathrm{RBC}}}{C_{\\mathrm{plasma}}} \\quad \\Rightarrow \\quad C_{\\mathrm{RBC}} = K\\,C_{\\mathrm{plasma}}.\n$$\n\n(a) Derive an expression for $C_{\\mathrm{WB}}$ in terms of $H$, $K$, and $C_{\\mathrm{plasma}}$. \n\n(b) For tacrolimus, take $K = 15$ as a plausible constant over the observed range. If $C_{\\mathrm{plasma}}$ remains unchanged between the two time points, compute the expected ratio $\\dfrac{C_{\\mathrm{WB,2}}}{C_{\\mathrm{WB,1}}}$ resulting solely from the change in $H$ from $H_1 = 0.40$ to $H_2 = 0.25$. Compare this expected ratio to the observed ratio $\\dfrac{C_{\\mathrm{WB,2}}}{C_{\\mathrm{WB,1}}} = \\dfrac{6}{8}$ and reason whether the anemia can explain most of the observed decrease in whole blood trough without implying underexposure.\n\n(c) Based on this reasoning, which of the following is the most appropriate interpretation and action regarding tacrolimus troughs during anemia?\n\nA. Whole blood tacrolimus troughs depend on hematocrit via RBC binding; with $K \\gg 1$, lowering $H$ reduces $C_{\\mathrm{WB}}$ even if $C_{\\mathrm{plasma}}$ is unchanged. The observed decrease is largely explained by anemia; dose escalation is not automatically warranted. Consider plasma tacrolimus measurement or hematocrit-adjusted interpretation.\n\nB. Whole blood tacrolimus troughs are independent of hematocrit because tacrolimus distributes predominantly in plasma; the lower trough indicates true underexposure and mandates dose increase.\n\nC. Anemia reduces hepatic metabolism and tacrolimus clearance, which should increase whole blood concentrations; the lower trough indicates nonadherence.\n\nD. RBC binding and hematocrit affect only peak tacrolimus levels, not troughs; anemia does not explain trough changes, so increasing the dose is required.\n\nE. The decrease in whole blood tacrolimus trough during anemia proves increased drug clearance; promptly increase the dose to restore the original trough value.",
            "solution": "Part (a): Begin with conservation of mass in the two-compartment mixture of red blood cells and plasma. The whole blood concentration is the volume-fraction-weighted average of compartment concentrations:\n$$\nC_{\\mathrm{WB}} = H\\,C_{\\mathrm{RBC}} + (1-H)\\,C_{\\mathrm{plasma}}.\n$$\nBy definition of the partition coefficient $K$,\n$$\nK = \\dfrac{C_{\\mathrm{RBC}}}{C_{\\mathrm{plasma}}} \\quad \\Rightarrow \\quad C_{\\mathrm{RBC}} = K\\,C_{\\mathrm{plasma}}.\n$$\nSubstitute $C_{\\mathrm{RBC}} = K\\,C_{\\mathrm{plasma}}$ into the mass balance:\n$$\nC_{\\mathrm{WB}} = H\\,(K\\,C_{\\mathrm{plasma}}) + (1-H)\\,C_{\\mathrm{plasma}} = C_{\\mathrm{plasma}}\\big[(1-H) + H\\,K\\big].\n$$\nThus, \n$$\nC_{\\mathrm{WB}}(H,K,C_{\\mathrm{plasma}}) = C_{\\mathrm{plasma}}\\left[(1-H) + H\\,K\\right].\n$$\n\nPart (b): With $K = 15$, compute the factor $\\Phi(H) = (1-H) + H\\,K$ at the two hematocrits.\n\nFor $H_1 = 0.40$:\n$$\n\\Phi(H_1) = (1-0.40) + 0.40\\times 15 = 0.60 + 6.00 = 6.60.\n$$\nFor $H_2 = 0.25$:\n$$\n\\Phi(H_2) = (1-0.25) + 0.25\\times 15 = 0.75 + 3.75 = 4.50.\n$$\nIf $C_{\\mathrm{plasma}}$ is unchanged, then the ratio of whole blood concentrations equals the ratio of these factors:\n$$\n\\dfrac{C_{\\mathrm{WB,2}}}{C_{\\mathrm{WB,1}}} = \\dfrac{\\Phi(H_2)}{\\Phi(H_1)} = \\dfrac{4.50}{6.60} \\approx 0.6818.\n$$\nThe observed ratio is\n$$\n\\dfrac{C_{\\mathrm{WB,2}}}{C_{\\mathrm{WB,1}}} = \\dfrac{6}{8} = 0.75.\n$$\nThe expected ratio from the hematocrit change alone ($\\approx 0.68$) is close to the observed ratio ($0.75$). The slight difference could be due to assay variability, small changes in $K$, or a modest change in $C_{\\mathrm{plasma}}$. Crucially, the majority of the decrease in $C_{\\mathrm{WB}}$ is explained by the reduction in $H$ when $K \\gg 1$, because RBC binding dominates whole blood measurement. Therefore, anemia can substantially lower whole blood tacrolimus troughs without necessarily indicating reduced exposure at the effect site; the unbound or plasma concentration may be unchanged.\n\nPart (c): Evaluate each option:\n\nA. This option correctly states the dependence of $C_{\\mathrm{WB}}$ on hematocrit through RBC binding and the partition coefficient. The derived expression \n$$\nC_{\\mathrm{WB}} = C_{\\mathrm{plasma}}\\big[(1-H) + H\\,K\\big]\n$$\nshows that when $K \\gg 1$, $C_{\\mathrm{WB}}$ is highly sensitive to $H$. The numerical calculation demonstrates that the observed decrease can be largely attributed to anemia. It appropriately advises against automatic dose escalation and suggests strategies (plasma measurement or hematocrit-adjusted interpretation) to avoid misinterpretation. Verdict — Correct.\n\nB. This option asserts independence of whole blood tacrolimus from hematocrit and emphasizes plasma predominance. This contradicts the mass balance and partitioning model and the empirical property that tacrolimus binds strongly to RBCs, yielding $K \\gg 1$. It would lead to inappropriate dose increases. Verdict — Incorrect.\n\nC. This option claims anemia reduces hepatic metabolism and tacrolimus clearance. Anemia does not generally reduce the intrinsic hepatic clearance of tacrolimus; if anything, reduced RBC binding would decrease whole blood concentrations for the same plasma concentration. The prediction that whole blood should increase is opposite to the derived dependence on $H$, and invoking nonadherence is unsupported. Verdict — Incorrect.\n\nD. This option claims RBC binding and hematocrit affect only peaks, not troughs. The equilibrium-based mixture relation applies at any sampling time once distribution has equilibrated, including trough, so $C_{\\mathrm{WB}}$ at trough is affected by $H$. Thus, anemia can explain trough changes. Verdict — Incorrect.\n\nE. This option interprets the lower trough as proof of increased clearance and calls for dose escalation. The calculation shows most of the decrease can be explained without invoking clearance changes; automatic dose escalation risks overexposure. Verdict — Incorrect.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}